BlueReg Group Case study Define & implement the European Health Authorities consultation strategy for a US-based client

Define & implement the European Health Authorities consultation strategy for a US-based client

25 November 2020
  • Drug Development
  • Drug Registration

BlueReg made recommendations to a US based client on which Health Authorities in the European Union (EU) would be most relevant to consult throughout the development of their product.

Following these recommendations, the client subsequently entrusted to BlueReg the authoring of a Briefing Package and the management of the regulatory procedure for a national Scientific Advice consultation on its behalf.

Register to download the Case study


    By sending this form, I agree that my personal data will be saved and processed according to data protection regulations and will be used only for commercial and marketing purposes only.

    Learn more


    BlueReg undertakes to comply with the regulations in force applicable to the processing of personal data and, in particular, Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 applicable as from 25 May 2018 (hereinafter, "the General Data Protection Regulations" or GPDR) and the national laws resulting therefrom.
    Any inquiries, correction or declaration of event related to personal data processed should be sent to:

    GDPR data request

    Thank you for your reply

    The file will be sent to you by email.

    Download

    Contact our experts today

    Composed of proven experts from the pharmaceutical industry, our team is ready to answer to your needs in any area of product development, commercialisation and early access programs, and life cycle management

    Make an enquiry